45% Of Breast Tumors Destroyed With Pertuzumab And Herceptin Combo Plus Chemotherapy
 

45% of women with pre-surgery early-stage HER2-positive breast cancer experienced a complete tumor reduction when given Pertuzumab and Herceptin plus chemotherapy (docetaxel) during a Phase II study evaluation, the NEOSPHERE trial. Researchers presented their finding at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS)...

More...